JESSICA BELLOWS: Open Payments
NPI 1457037954 · MCKINNEY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,048 in 115 payments from 20 companies in 2025. Trend: 2023 $600 · 2024 $2,038 · 2025 $2,048
Food & beverage: $2,048
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 19 | $457 |
| ABBVIE INC. | 19 | $196 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $162 |
| Lundbeck LLC | 13 | $159 |
| Corium, LLC | 6 | $158 |
| Janssen Pharmaceuticals, Inc | 11 | $136 |
| Teva Pharmaceuticals USA, Inc. | 4 | $118 |
| Tris Pharma Inc | 5 | $106 |
| Vanda Pharmaceuticals Inc. | 4 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
Products named: INGREZZA, REXULTI, VRAYLAR, CAPLYTA, Azstarys, SPRAVATO, Dyanavel XR, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
